Edition:
United Kingdom

Cymabay Therapeutics Inc (CBAY.OQ)

CBAY.OQ on NASDAQ Stock Exchange Global Select Market

5.82USD
16 Aug 2019
Change (% chg)

$-0.05 (-0.85%)
Prev Close
$5.87
Open
$5.90
Day's High
$5.99
Day's Low
$5.78
Volume
211,366
Avg. Vol
311,966
52-wk High
$14.00
52-wk Low
$4.82

Latest Key Developments (Source: Significant Developments)

Cymabay Reports Q2 Loss Per Share $0.35
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.35.Q2 EARNINGS PER SHARE ESTIMATE $-0.37 -- REFINITIV IBES DATA.HELD $241.2 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AT JUNE 30, 2019.EXISTING CASH IS EXPECTED TO FUND CURRENT OPERATING PLAN INTO 2021.  Full Article

CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis
Tuesday, 18 Jun 2019 

June 18 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY THERAPEUTICS ANNOUNCES IND TO COMMENCE A CLINICAL STUDY OF SELADELPAR TO TREAT PRIMARY SCLEROSING CHOLANGITIS.CYMABAY THERAPEUTICS - FDA CLEARANCE OF COMPANY'S INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR SELADELPAR TO TREAT PRIMARY SCLEROSING CHOLANGITIS.  Full Article

Cymabay Therapeutics Says Seladelpar Appears To Be Safe And Well-Tolerated Across All Doses
Tuesday, 11 Jun 2019 

June 11 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY THERAPEUTICS REPORTS TOPLINE 12-WEEK DATA FROM AN ONGOING PHASE 2B STUDY OF SELADELPAR IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS.CYMABAY THERAPEUTICS INC - REDUCTIONS IN LIVER FAT WERE MINIMAL AND NOT SIGNIFICANT COMPARED TO PLACEBO.CYMABAY THERAPEUTICS INC - SELADELPAR APPEARS TO BE SAFE AND WELL-TOLERATED ACROSS ALL DOSES.CYMABAY THERAPEUTICS INC - BLINDED STUDY WILL CONTINUE TO 52-WEEK LIVER BIOPSY.CYMABAY THERAPEUTICS INC - BLINDED STUDY WILL CONTINUE TO 52-WEEK LIVER BIOPSY.CYMABAY THERAPEUTICS INC - REDUCTIONS IN MARKERS OF LIVER INJURY WERE ROBUST AND CLINICALLY MEANINGFUL.  Full Article

Cymabay Therapeutics Says Seladelpar Granted Breakthrough Therapy Designation By FDA
Friday, 15 Feb 2019 

Feb 15 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY THERAPEUTICS ANNOUNCES SELADELPAR GRANTED BREAKTHROUGH THERAPY DESIGNATION BY THE FDA FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS.  Full Article

CymaBay Therapeutics Q1 Loss Per Share $0.32
Tuesday, 8 May 2018 

May 8 (Reuters) - CymaBay Therapeutics Inc ::CYMABAY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.32.Q1 EARNINGS PER SHARE VIEW $-0.14 -- THOMSON REUTERS I/B/E/S.QTRLY LOSS PER SHARE $0.32.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $229.5 MILLION AT END OF Q1 OF 2018.EXISTING CASH IS EXPECTED TO FUND CYMABAY'S CURRENT OPERATING PLAN INTO 2021.  Full Article

Cymabay Reports Q4 Loss Per Share $0.11
Thursday, 15 Mar 2018 

March 15 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY REPORTS FOURTH QUARTER AND FISCAL 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.11.Q4 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.QTRLY COLLABORATION REVENUE $5.2 MILLION.  Full Article

Cymabay Therapeutics Receives $5 Mln Milestone Payment For Arhalofenate From Kowa Pharmaceuticals America
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY THERAPEUTICS RECEIVES $5 MILLION MILESTONE PAYMENT FOR ARHALOFENATE FROM KOWA PHARMACEUTICALS AMERICA.  Full Article

CymaBay Therapeutics Files For Mixed Shelf Of Up To $200 Mln
Friday, 29 Dec 2017 

Dec 29 (Reuters) - CymaBay Therapeutics Inc ::CYMABAY THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING.  Full Article

CymaBay reports Q3 loss per share $0.21
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - CymaBay Therapeutics Inc ::CymaBay reports third quarter 2017 financial results and corporate updates.Q3 loss per share $0.21.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.CymaBay Therapeutics - ‍cash, cash equivalents and marketable securities totaled $102.2 million at end of Q3 of 2017, compared to $17.0 million at Dec 31, 2016​.CymaBay Therapeutics Inc - ‍existing cash expected to fund operations into 2019​.  Full Article

Cymabay Therapeutics names Sujal Shah CEO
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Cymabay Therapeutics Inc :Cymabay announces the appointment of Sujal Shah as president and chief executive officer.Cymabay Therapeutics Inc says ‍sujal Shah has been serving as interim president and chief executive officer since March 2017​.  Full Article